A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects

Diabetes, Obesity and Metabolism

Volumn 12, Issue 8, 2010, Pages 659-664

  Khedkar, A ^a   Iyer, H ^a   Anand, A ^a   Verma, M ^a   Krishnamurthy, S ^a   Savale, S ^b   Atignal, A ^b  

^a Biocon Limited   (India)

^b Clinigene International Limited   (India)

Author keywords

Insulin; Oral insulin; Pharmacodynamics; Pharmacokinetics; Type 2 diabets mellitus

Indexed keywords

C PEPTIDE; GLUCOSE; IMMUNOREACTIVE INSULIN; IN 105; INSULIN; METFORMIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; SIDE EFFECT; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77958084962     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01213.x     Document Type: Article

References (12)

1. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004; 6: 510-517.
2. Heinemann L, Jacques Y. Oral insulins and buccal insulins: a critical repraisal. J Diabetes Sci Technol 2009; 3: 568-584.
3. Iyer H, Khedkar A, Verma M. Oral insulin-a review of current status. Diabetes Obes Metab 2010; 12: 179-185.
4. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187-218.
5. Escandon JC, Robbins DC. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 1987; 36: 1167-1172.
6. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999; 48: 99-105.
7. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31: 1927-1932.
8. Suryanarayan S, Khedkar A, Vedala A et al. Pharmacokinetics and pharmacodynamics of a single oral dose of the insulin analog IN-105, in tablet form, in normal healthy volunteers, in the presence of food (Abstract). Diabetologia 2007; 50(Suppl. 1): S95-S96.
9. Moses RG, Gomis R, Frandsen KB, Schlinger J, Devov I. Flexible meal related dosing with repaglinide facilitates glycemic control in Therapy näi{dotless}ve type 2 diabetes. Diabetes Care 2001; 24: 11-15.
10. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first and secondphase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-5997.
11. Perriello G, Pampanelli S, Porcellati F et al. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet Med 2005; 22: 606-611.
12. Rave K, Heise T, Pfutzner A, Anders H, Boss AH. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007; 30: 2307-2308.